Typhoid Fever
Table of Contents
1. Overview
Typhoid fever (also called enteric fever) is a systemic bacterial infection caused by Salmonella enterica serotype Typhi. An estimated 11–21 million cases occur globally each year, resulting in approximately 128,000–161,000 deaths. Paratyphoid fever, caused by S. Paratyphi A, B, or C, causes a clinically similar but typically milder illness.
Typhoid is a disease of contaminated food and water in settings with inadequate sanitation. It is one of the most important bacterial causes of fever in returning travelers from South Asia, sub-Saharan Africa, and Southeast Asia. The illness is characterized by sustained high fever, abdominal pain, relative bradycardia, splenomegaly, and a distinctive rash called "rose spots." Untreated, mortality reaches 10–30%; with appropriate antibiotic therapy, case fatality falls below 1%.
The emergence of extensively drug-resistant (XDR) typhoid — particularly a clone originating in Pakistan and spreading internationally — has complicated treatment, making vaccination increasingly important as a public health tool.
2. Pathogen Biology
Salmonella enterica serotype Typhi is a Gram-negative, facultative anaerobic, non-spore-forming rod in the family Enterobacteriaceae. It is a human-restricted pathogen — humans are the only reservoir and primary host.
Virulence Mechanisms
After ingestion, S. Typhi transits the stomach and enters the small intestine. The organism invades intestinal epithelium via M cells overlying Peyer's patches and is taken up by macrophages. Rather than being killed, S. Typhi survives and multiplies within mononuclear phagocytes using a type III secretion system (T3SS, encoded on Salmonella Pathogenicity Island 1 and 2) that injects bacterial effector proteins into host cells to subvert phagolysosome fusion and innate immune signaling.
A unique virulence feature of S. Typhi is the Vi (virulence) polysaccharide capsule, which inhibits complement deposition and phagocytosis and is the basis for the Vi polysaccharide vaccine. After an incubation period of 7–21 days (typically 10–14 days), bacteria re-enter the bloodstream from mesenteric lymph nodes in a primary bacteremia. Secondary bacteremia seeds the liver, gallbladder, spleen, bone marrow, and intestinal lymphoid tissue (Peyer's patches), causing the systemic illness.
Chronic Carriage
Approximately 1–5% of patients become chronic carriers — individuals who continue to shed S. Typhi in stool or urine for more than 1 year following acute infection. The gallbladder, particularly in patients with gallstones or structural abnormalities, serves as the primary reservoir for chronic carriage. Chronic carriers are key drivers of ongoing typhoid transmission, as illustrated by the historical case of "Typhoid Mary" (Mary Mallon).
3. Transmission & Epidemiology
Typhoid fever is transmitted exclusively via the fecal-oral route — through the consumption of food or water contaminated by the feces or urine of acutely infected individuals or chronic carriers. There is no animal reservoir.
Global Distribution
Typhoid is endemic in South Asia (India, Pakistan, Bangladesh, Nepal account for the majority of global cases), sub-Saharan Africa, and parts of Southeast Asia. South Asia alone accounts for approximately 70% of the global typhoid burden. The disease is rare in high-income countries with treated water supplies and robust sanitation systems, occurring primarily in travelers returning from endemic regions and in communities with compromised water infrastructure.
Antimicrobial Resistance
The emergence of multidrug-resistant (MDR) typhoid — resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (the traditional first-line drugs) — began in the 1990s. More alarming is the XDR typhoid strain (H58 clade 4.3.1) that emerged in Pakistan in 2016, additionally resistant to fluoroquinolones and third-generation cephalosporins, leaving azithromycin and carbapenems as the only reliable oral and parenteral options, respectively. XDR typhoid has since spread to multiple countries.
A 2018 genome study (Klemm and colleagues) described how this strain arose. More than 300 XDR typhoid cases had appeared in Sindh province, Pakistan, since November 2016, and the sequenced isolates were almost identical copies of one H58 clone. The strain was already multidrug-resistant through a resistance region in its chromosome; it became extensively drug-resistant in a single step by picking up a plasmid (a small, shareable loop of DNA) that carries the blaCTX-M-15 extended-spectrum beta-lactamase gene and the qnrS fluoroquinolone resistance gene, encoding resistance to fluoroquinolones and third-generation cephalosporins. Very similar plasmids had already been found in other gut bacteria from widely separated places, and the study also reported a travel-associated XDR case in the United Kingdom.
4. Symptoms by Phase
The clinical course of typhoid fever classically progresses through stepwise weekly phases, though this pattern is not always distinct in practice:
Week 1 — Prodrome and Rising Fever
Gradual onset of fever that rises in a step-ladder pattern, reaching 39–40°C. Associated symptoms: malaise, headache, anorexia, myalgias, abdominal discomfort, and non-productive cough. Relative bradycardia (pulse slower than expected for the degree of fever, a finding called Faget's sign) is a classic but not universally present feature. Leukopenia is typical, helping distinguish typhoid from bacterial pyogenic infections.
Week 2 — Peak Fever and Abdominal Signs
Sustained plateau fever (39–40°C), increasing toxicity, and abdominal findings: diffuse abdominal tenderness, hepatosplenomegaly in the majority of patients, and constipation (more common than diarrhea in the early stages). Rose spots: faint salmon-colored macular or maculopapular rash appearing on the trunk (abdomen, lower chest) in approximately 30–50% of patients, lasting 2–5 days before fading; difficult to see on darker skin tones. Mental status changes — confusion, delirium, prostration ("typhoid state") — may appear in severe cases.
Week 3 — Complications or Defervescence
The critical period. Without treatment, life-threatening complications can develop: intestinal hemorrhage from necrosis of Peyer's patches, intestinal perforation (most feared complication), hepatitis, myocarditis, or neurologic involvement. With adequate antibiotic treatment, fever begins to defervescence around days 5–7 and the patient improves over 1–2 weeks. Relapses occur in 5–10% of patients 2–3 weeks after clinical recovery.
5. Diagnosis
Diagnosis requires clinical suspicion based on fever in a returning traveler or resident of an endemic area, combined with laboratory confirmation.
Blood Culture (Gold Standard)
Blood culture is the most reliable diagnostic test, with sensitivity of 80–90% in the first week of illness (before antibiotics). Sensitivity decreases substantially after antibiotic administration. Multiple blood culture sets (3 sets at 12-hour intervals) increase diagnostic yield. Culture requires 2–5 days for growth of S. Typhi.
Bone Marrow Culture
Bone marrow aspirate culture is the most sensitive test for typhoid fever (sensitivity ~90%) even after several days of antibiotic treatment. It is invasive but valuable when blood cultures are negative and typhoid is strongly suspected.
Widal Test
The Widal agglutination test detects antibodies against O and H antigens of S. Typhi. Widely used in resource-limited settings due to low cost, but has poor specificity (false positives in prior vaccination, other Salmonella infections, and endemic populations with high background serology), variable sensitivity, and requires paired samples for reliable interpretation. Not recommended as the sole diagnostic test in guideline-adherent practice.
Typhoid Rapid Diagnostic Tests (RDTs)
Rapid antibody tests in lateral-flow format detect anti-S. Typhi immunoglobulin M (IgM) antibodies. Sensitivity varies widely (50–80%) by study and population; they perform better in the second week of illness. Rapid antibody tests that detect anti-O9 antibodies have slightly better performance. RDTs are used in endemic low-resource settings; blood culture remains the reference test where it is available.
Polymerase Chain Reaction
Quantitative polymerase chain reaction (PCR) for S. Typhi DNA in blood can detect low levels of bacteremia and may identify cases earlier than culture; high sensitivity and specificity, but not yet standardized or widely available.
6. Treatment
Antibiotic Selection Based on Susceptibility
Treatment guidelines base the antibiotic choice on local resistance patterns. Given the spread of XDR typhoid from South Asia, first-choice (empiric) therapy takes into account where the infection was acquired:
- Fluoroquinolone-susceptible typhoid: Ciprofloxacin 500 mg PO twice daily × 5–7 days, or ofloxacin 400 mg PO twice daily × 5 days — highly effective (cure rates >95%); fluoroquinolone resistance is common in infections acquired in South Asia, including Pakistan.
- Fluoroquinolone-resistant (non-XDR) typhoid: Azithromycin 1 g PO on day 1, then 500 mg daily × 6 days (for uncomplicated typhoid); ceftriaxone 2–4 g intravenous (IV) daily × 10–14 days for severe disease.
- XDR typhoid (Pakistan-origin, resistant to fluoroquinolones + cephalosporins): Azithromycin 20 mg/kg/day PO (max 1 g) × 7 days for uncomplicated disease. Meropenem 1 g intravenous every 8 hours for severe or complicated XDR typhoid.
- Pediatric dosing: Azithromycin 20 mg/kg/day and ceftriaxone 75 mg/kg/day are preferred in children; fluoroquinolones are generally not the first choice in children under 18 because of theoretical joint toxicity, though they are used when benefits outweigh risks.
- Dexamethasone (3 mg/kg loading dose, then 1 mg/kg every 6 hours for 48 hours) is recommended for patients with severe typhoid complicated by delirium, obtundation, stupor, coma, or shock — reduces mortality in severe disease.
Chronic Carriage Treatment
Fluoroquinolones for 28 days (ciprofloxacin 750 mg PO twice daily) achieve microbiologic cure in approximately 80% of carriers without structural biliary disease. Cholecystectomy combined with antibiotic therapy is required for carriers with gallstones or other biliary pathology unresponsive to antibiotics.
7. Home & Supportive Care
Patients with uncomplicated typhoid who are able to take oral antibiotics and fluids can often be managed at home with close follow-up:
- Hydration: Typhoid causes significant insensible fluid losses through fever; a fluid intake of 2.5–3 liters daily is the usual target. Oral rehydration solution (ORS) is used if diarrhea is present.
- Fever management: Paracetamol every 6 hours is the usual fever medicine. Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase gastrointestinal bleeding risk in a disease that can affect Peyer's patches.
- Diet: Soft, easily digested foods such as rice porridge (brown rice can be cooked soft), bananas and cooked vegetables. High-fiber foods, raw vegetables and spicy foods are usually left out during acute illness; high residue can worsen bowel wall stress where ulceration may be occurring.
- Activity restriction: Complete bed rest is usual during the febrile phase; physical exertion can theoretically increase risk of intestinal perforation.
- Strict hygiene: Hand washing after toilet use is critical to prevent transmission to household contacts. Food preparation is usually handled by an uninfected person until the patient is culture-negative.
- Warning signs that hospitals treat as urgent: Severe abdominal pain (especially with rebound tenderness — may indicate perforation), signs of bleeding (rectal blood or melaena), altered consciousness, respiratory distress, or failure to improve after 5 days of antibiotics.
8. Complications
- Intestinal perforation: Occurs in 1–3% of untreated cases (more common in children and adolescents) from necrosis and ulceration of Peyer's patches in the terminal ileum. Presents as sudden worsening of abdominal pain, rigidity, and peritoneal signs. Requires emergency laparotomy with primary repair or segmental resection; mortality even with surgery is 10–30%.
- Intestinal hemorrhage: Significant gastrointestinal (GI) bleeding from ulcerated Peyer's patches in approximately 1–3%; managed with transfusion and hemostasis; may require surgery.
- Hepatitis: Transaminase elevation in up to 50% of cases; rarely progresses to hepatic failure.
- Myocarditis and pericarditis: Occur in approximately 1–5%; may manifest as arrhythmia, conduction defects, or heart failure.
- Neuropsychiatric typhoid: Encephalopathy, meningism, delirium, and psychosis in severe disease; cranial nerve palsies, cerebellar ataxia, and Guillain-Barré syndrome are rare.
- Relapse: Occurs in 5–10% of treated patients, typically 2–3 weeks after defervescence. Relapses are usually milder than the primary episode and are treated with antibiotics chosen by sensitivity testing.
- Hemophagocytic lymphohistiocytosis (HLH): Rare but life-threatening complication of typhoid fever, presenting as unremitting fever, cytopenia, and hyperferritinemia.
9. Prevention & Vaccines
Sanitation and Water Safety
The most effective long-term prevention is safe water, sanitation, and hygiene (WASH): chlorinated water supplies, sewage treatment, food safety, and hand hygiene education. These interventions have eliminated endemic typhoid from high-income countries.
Travel Precautions
Travel health guidance for endemic regions describes strict food and water precautions: drinking only bottled or boiled water, eating only thoroughly cooked food and pasteurized dairy, and leaving out raw fruits and vegetables that cannot be peeled and street food. These measures substantially reduce (but do not eliminate) risk.
Typhoid Conjugate Vaccine (TCV) — Preferred
Typhoid conjugate vaccines (Vi-tetanus toxoid conjugate vaccine, TCV) couple the Vi polysaccharide antigen to a carrier protein (tetanus toxoid), producing T-cell-dependent immunity, longer-lasting protection, and immunogenicity in children under 2 years. A Vi-tetanus toxoid conjugate vaccine prequalified by the World Health Organization (WHO) showed 81.6% efficacy in a phase 3 trial in Nepal. In Malawi, the final analysis of a phase 3 trial in 28,130 children aged 9 months to 12 years found 78.3% efficacy over a median 4.3 years of follow-up (70.6% in children aged 9 months to 2 years, 79.6% at 2–4 years and 79.3% at 5–12 years). It is given from 6 months of age as a single dose. Protection wanes over time: in a 5-year follow-up of a trial in Bangladeshi children (TyVOID), the estimated effectiveness of a single dose was 50% in years 3–5 after vaccination, and 24% in the youngest children (under 7 years at the fever visit). Antibody levels fell fastest in children vaccinated before age 2, and the authors write that a booster dose around school entry age might be needed for them. The World Health Organization recommends TCV as the preferred typhoid vaccine for programmatic use.
Vi Capsular Polysaccharide Vaccine
Single IM dose; efficacy approximately 60–70%, duration of protection 3 years. Not immunogenic in children under 2 years due to T-cell independence. Used in travelers from age 2 years; repeat doses are given every 3 years with ongoing exposure. A 2018 Cochrane review of randomized trials found that one dose prevented 69% of typhoid cases in the first year (3 trials, 99,979 participants) and 59% in the second year (4 trials, 194,969 participants), in people aged 2 to 55 years.
Oral Live Attenuated Ty21a Vaccine
Live attenuated oral vaccine; 4 capsules taken on alternate days. Efficacy approximately 50–67% in endemic populations; 3–7 years protection. It is kept refrigerated and is contraindicated in immunocompromised individuals and during antibiotic use. Used in travelers from age 6 years. The same Cochrane review found that a three-dose schedule of Ty21a prevented about half of typhoid cases over the first 3 years (cumulative efficacy 50%; 4 trials, 235,239 participants aged 3 to 44 years); fever was probably more common after vaccination. The review found no reported serious adverse effects in the randomized trials of any of the typhoid vaccines studied.
Key Research Papers
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–353. — PubMed PMID: 15298225
- Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med. 2002;347:1770–1782. — PubMed PMID: 12456854 · doi:10.1056/NEJMra020201
- Pitzer VE, Bowles CC, Baker S, et al. Predicting the impact of vaccination on the transmission dynamics of typhoid in South Asia: a mathematical modeling study. PLoS Negl Trop Dis. 2014;8:e2642. — PubMed PMID: 24416466 · doi:10.1371/journal.pntd.0002642
- Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. N Engl J Med. 2019;381:2209–2218. — PubMed PMID: 31800986 · doi:10.1056/NEJMoa1905047
- Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018;9:e00105-18. — PubMed PMID: 29463654 · doi:10.1128/mBio.00105-18
- Britto C, Pollard AJ, Voysey M, Blohmke CJ. An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age-stratified disease occurrence. Clin Infect Dis. 2017;64:1604–1611. — PubMed PMID: 28369224 · doi:10.1093/cid/cix229
- Darton TC, Blohmke CJ, Moorthy VS, et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis. 2015;15:840–851. — PubMed PMID: 26026195 · doi:10.1016/s1473-3099(15)00068-7
- Andrews JR, Ryan ET. Diagnostics for invasive Salmonella infections: current challenges and future directions. Vaccine. 2015;33:C8–C15. — PubMed PMID: 25937611 · doi:10.1016/j.vaccine.2015.02.030
- Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015;385:1136–1145. — PubMed PMID: 25458731 · doi:10.1016/s0140-6736(13)62708-7
- Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;5:CD001261. — PubMed PMID: 29851031 · doi:10.1002/14651858.CD001261.pub4
- Patel PD, Liang Y, Meiring JE, et al. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet. 2024;403:459–468. — PubMed PMID: 38281499 · doi:10.1016/S0140-6736(23)02031-7
- Qadri F, Khanam F, Zhang Y, et al. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. Lancet. 2024;404:1419–1429. — PubMed PMID: 39396349 · doi:10.1016/S0140-6736(24)01494-6
PubMed Topic Searches
- PubMed: Typhoid fever review
- PubMed: Salmonella Typhi pathogenesis
- PubMed: XDR typhoid extensively drug-resistant
- PubMed: Typhoid conjugate vaccine efficacy
- PubMed: Typhoid intestinal perforation
- PubMed: Enteric fever diagnosis blood culture
- PubMed: Typhoid azithromycin treatment
- PubMed: Typhoid global burden epidemiology
Connections
- Infectious Disease
- Dengue Fever
- Malaria
- Sepsis
- Clostridioides difficile
- Tuberculosis
- Common Cold
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
- Hepatitis B
- Lyme Disease
- Strep Throat
- Shingles
- Norovirus
- Immune Boosting
- Vitamin C
- Garlic
- Typhoid Fever: Step-by-Step Progression — week-by-week course and complications.
- Salmonella: Symptoms and Disease Spectrum — typhoidal versus non-typhoidal Salmonella.
- Treating Salmonella: Rehydration and Antibiotics — azithromycin, ceftriaxone, and options for XDR typhoid.